Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan CRO CMIC Acquires Daiichi Sankyo Shizuoka Facility

This article was originally published in PharmAsia News

Executive Summary

Japan's largest contract research organization CMIC Nov. 30 announced an agreement to acquire a facility from Daiichi Sankyo. The 210,000-square meter facility based in Shimada, Shizuoka Prefecture manufactures antibacterial agent Cravit (levofloxacin) and hemostatic drug Transamin (tranexamic). Daiichi plans to move some of its production to other sites and keep the rest for contract manufacture for SMIC. According to the deal, SMIC plans to acquire all outstanding shares by April 2010; the two companies did not disclose further terms . (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts